Research advances on the role of mitochondrial dysfunction in sepsis-acquired weakness.
10.3760/cma.j.cn121430-20250724-00700
- Author:
Xiujun CHANG
1
;
Zhaoxuan GUO
1
;
Jiayu FANG
1
;
Xian QIN
1
;
Fan ZENG
1
;
Yunping LAN
1
Author Information
1. Critical Care Medicine Center, Affiliated Hospital of University of Electronic Science and Technology of China (Sichuan Provincial People's Hospital), Chengdu 610072, China.
- Publication Type:English Abstract
- MeSH:
Humans;
Sepsis/metabolism*;
Mitochondria/metabolism*;
Muscle Weakness/etiology*;
Oxidative Stress;
Oxidative Phosphorylation
- From:
Chinese Critical Care Medicine
2025;37(10):976-981
- CountryChina
- Language:Chinese
-
Abstract:
Sepsis-acquired weakness (SAW) is a common complication in critically ill patients, yet significant gaps remain in both mechanistic understanding and therapeutic interventions for this condition. SAW not only prolongs the duration of mechanical ventilation and hospitalization but is also closely associated with increased mortality. Even if these SAW patients survive, they often experience long-term physical dysfunction after hospital discharge, leading to diminished quality of life. Emerging evidence suggests that sustained mitochondrial dysfunction may constitute a pivotal pathophysiological basis for the development and progression of SAW, primarily encompassing five key aspects: dysregulated mitochondrial quality control (MtQC), impaired oxidative phosphorylation (OXPHOS), exacerbated oxidative stress, disrupted Ca2+; homeostasis, and their mediation of diverse myofiber injuries. This article systematically elucidates the central role of mitochondrial dysfunction in the pathogenesis of SAW. Furthermore, we explore potential therapeutic strategies targeting mitochondrial function, including mitigating mitochondrial oxidative stress, optimizing nutritional support, and supplementing with muscle-derived mesenchymal stem cells. These insights provide a critical theoretical framework for understanding SAW mechanisms and developing clinical interventions, with particular emphasis on the translational value of mitochondrial-targeted therapies in improving outcomes for septic patients.
